Genocea Biosciences traded at $0.01 this Wednesday July 6th, decreasing $0.002 or 11.95 percent since the previous trading session. Looking back, over the last four weeks, Genocea Biosciences lost 26.32 percent. Over the last 12 months, its price fell by 99.31 percent. Looking ahead, we forecast Genocea Biosciences to be priced at 0.01 by the end of this quarter and at 0.01 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.01
Daily Change
-11.95%
Yearly
-99.31%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agenus 2.42 0.01 0.41% -55.10%
Baxter International 65.38 -0.01 -0.02% -20.12%
Bluebird Bio 4.78 -0.27 -5.27% -84.63%
Cytokinetics 43.92 0.02 0.05% 122.15%
Plus Therapeutics, Inc. 0.52 0.01 2.06% -78.83%
Genocea Biosciences 0.01 -0.002 -11.95% -99.31%
Glaxosmithkline 43.06 -0.24 -0.55% 7.01%
Infinity Pharmaceuticals 0.60 -0.01 -1.71% -78.19%
Merck & Co 93.71 1.07 1.16% 19.28%
Moderna Inc 160.29 4.75 3.05% -27.76%
Mirati Therapeutics 70.27 -1.69 -2.35% -55.79%
Novavax 62.82 -1.48 -2.29% -66.19%
Pfizer 52.38 0.74 1.43% 33.11%
Prothena 29.88 0.19 0.64% -43.90%

Indexes Price Day Year
USND 11382 59.43 0.52% -22.39%
US2000 1731 -9.84 -0.56% -23.14%

Genocea Biosciences
Genocea Biosciences, Inc. is a biopharmaceutical company that is engaged in discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) technology platform. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Its programs include GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. Its GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral T cells (NPTs). The GEN-011 NPTs is preferred for ATLAS-identified anti-tumor antigens that are used to manufacture a peripheral blood-derived, tumor-specific T cell therapy.